Castle Biosciences, Inc.: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Castle Biosciences, Inc. listata cu simbolul US.CSTL ==Descriere companie== Castle Biosciences, Inc. (www.castlebiosciences.com) is a commercial-stage dermatological cancer company. The Company provides physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company markets its three dermatologic products, DecisionDx-Melanoma, DecisionDx-SCC and DecisionDx DiffDx-Melan...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Castle Biosciences, Inc. (www.castlebiosciences.com) is a commercial-stage dermatological cancer company. The Company provides physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company markets its three dermatologic products, DecisionDx-Melanoma, DecisionDx-SCC and DecisionDx DiffDx-Melanoma. It also market DecisionDx-UM, a gene expression profiling (GEP) test. It developed and market DecisionDx-Melanoma to healthcare providers for use with patients diagnosed with invasive cutaneous melanoma. It developed DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. It developed DecisionDx DiffDx-Melanoma, a GEP test designed to be used as an adjunct to histopathology when the distinction between a benign lesion and melanoma is uncertain. | Castle Biosciences, Inc. (www.castlebiosciences.com) is a commercial-stage dermatological cancer company. The Company provides physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company markets its three dermatologic products, DecisionDx-Melanoma, DecisionDx-SCC and DecisionDx DiffDx-Melanoma. It also market DecisionDx-UM, a gene expression profiling (GEP) [[test]]. It developed and market DecisionDx-Melanoma to healthcare providers for use with patients diagnosed with invasive cutaneous melanoma. It developed DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with [[one]] or more risk factors. It developed DecisionDx DiffDx-Melanoma, a GEP test designed to be used as an adjunct to histopathology when the distinction between a benign lesion and melanoma is uncertain. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||